Jefferies cuts price target on Telix Pharmaceuticals following quarterly update
Wed 21:57
BUZZ-Jefferies cuts price target on Telix Pharmaceuticals following quarterly update ** Jefferies cuts its price target on Telix Pharmaceuticals TLX.AX to A$31.50 from A$32 and maintains "buy" rating following the company's Q3 update
** Brokerage cuts FY27 NPAT forecast to $2 million from $5 million
** Says uncertainty around the timing of its kidney cancer imaging candidate Zircaix resubmission to US FDA continues to limit near-term valuation upside
** Jefferies notes FY26 revenue guidance of $950 million to $970 million remains unchanged
** 12 of 13 analysts rate the stock 'buy' or higher and one 'hold' with a median price target of A$22.00 - LSEG-compiled data
** YTD, stock up 29.6%, as of last close
(Reporting by Paridhi Minda in Bengaluru)
Recent news on Telix Pharmaceuticals
See all newsJefferies cuts price target on Telix Pharmaceuticals following quarterly update
Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue
Brief: Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Education Agreement To Advance Psma-Informed Prostate Care
Australia's Telix rises after dosing first US patients with brain cancer imaging drug